Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.

Children put hands together.

The team, led by Professor Matthew Snape from the Oxford Vaccine Group at the University of Oxford, aims to determine how many children and teenagers have been infected with Covid-19, and what proportion of those have had symptoms. The research will also determine how many children and teenagers have not yet been infected and may remain susceptible to Covid-19 when lockdown measures are relaxed. 

Professor Matthew Snape, Chief Investigator on the study, said:

“To understand the current coronavirus pandemic, we need to work out how many people are becoming infected without showing any symptoms.”

‘What’s the STORY?’ was set up in 2019 as a pilot study to evaluate the UK immunisation programme, but it has now been adapted in response to the Covid-19 pandemic.

This new funding allows the project to expand to include new study sites and recruit an additional 1200 children and teenagers (aged 0-19 years) from across England. The team will also test samples already collected and these data, along with medical histories of Covid-19 symptoms, will provide valuable information into the levels of virus circulating in this segment of the population.

Professor Snape continues:

“With this study we will systematically study the proportion of children and teenagers with immunity against this virus during the course of the pandemic.”

Understanding the prevalence of Covid-19 in the community is vital to supporting public health in response to the pandemic, including in children and teenagers, who are mostly spared the worst of the disease but could be spreading the disease to others. 

Professor Snape concludes:

“This information is vital to informing public policy about how to best manage this devastating outbreak.”

‘What’s the STORY?’ is an ongoing research study led by Oxford Vaccine Group in collaboration with Public Health England (PHE) and a network of clinical sites in Bradford, Bristol, Leeds, Manchester, Sheffield, Southampton and St George’s, London.

A key aspect of this project is the need to assess a representative cohort of children and young people, in order to give an accurate “snapshot” of the wider population. The study team are keen to engage a range of individuals and must ensure that the group tested is not biased towards people who think they may have been infected with Covid-19, and for this reason, the study team will not provide test results to participants. 

Existing sites are primarily recruiting through mail out by invitation letters to selected postcodes, and eligible individuals from the catchment areas of each study site have been or will soon be contacted with information about the project. However broader recruitment to new sites is expected to open within the next few weeks, and updates will be available on the study website: whatsthestory.web.ox.ac.uk.

Please Support Now:

Oxford has over 100 researchers working on the urgent response to the Coronavirus outbreak. Public donations of any size will be rapidly put to use in our frontline research.

Please make a gift today >

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.